Thomas B. Cooper

25.6k total citations · 2 hit papers
342 papers, 19.5k citations indexed

About

Thomas B. Cooper is a scholar working on Psychiatry and Mental health, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Thomas B. Cooper has authored 342 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Psychiatry and Mental health, 106 papers in Pharmacology and 93 papers in Cellular and Molecular Neuroscience. Recurrent topics in Thomas B. Cooper's work include Schizophrenia research and treatment (71 papers), Neurotransmitter Receptor Influence on Behavior (70 papers) and Treatment of Major Depression (70 papers). Thomas B. Cooper is often cited by papers focused on Schizophrenia research and treatment (71 papers), Neurotransmitter Receptor Influence on Behavior (70 papers) and Treatment of Major Depression (70 papers). Thomas B. Cooper collaborates with scholars based in United States, Canada and United Kingdom. Thomas B. Cooper's co-authors include J. John Mann, Marc Laruelle, Pál Czobor, Lawrence S. Kegeles, Basalingappa L. Hungund, Leslie Citrome, Anissa Abi‐Dargham, Jeffrey A. Lieberman, Jan Volavka and John H. Krystal and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Thomas B. Cooper

338 papers receiving 18.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased baseline occupancy of D ₂ receptors by dopamine in schizophrenia

2000 765 citations Lawrence S. Kegeles, Thomas B. Cooper et al. profile →
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

2004 764 citations Deepak Cyril D’Souza, Edward Perry et al. Neuropsychopharmacology profile →

Peers

Countries citing papers authored by Thomas B. Cooper

Since Specialization

Citations

This map shows the geographic impact of Thomas B. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas B. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas B. Cooper more than expected).

Fields of papers citing papers by Thomas B. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas B. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas B. Cooper. The network helps show where Thomas B. Cooper may publish in the future.

Co-authorship network of co-authors of Thomas B. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas B. Cooper. A scholar is included among the top collaborators of Thomas B. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas B. Cooper. Thomas B. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression 2020 ·JAMA Network Open ·Matthew S. Milak, (unknown), Zhengchao Dong, Lawrence S. Kegeles, Michael F. Grunebaum, R. Todd Ogden, Xuejing Lin, (unknown), Raymond F. Suckow, Thomas B. Cooper, John G. Keilp, Xiangling Mao, Dikoma C. Shungu, J. John Mann	43
2	Ketamine metabolite pilot study in a suicidal depression trial 2019 ·Journal of Psychiatric Research ·Michael F. Grunebaum, Hanga Galfalvy, Tse‐Hwei Choo, (unknown), Ainsley K. Burke, Raymond F. Suckow, Thomas B. Cooper, J. John Mann	35
3	ANXIETY IN MAJOR DEPRESSION AND CEREBROSPINAL FLUID FREE GAMMA-AMINOBUTYRIC ACID 2014 ·Depression and Anxiety ·J. John Mann, María A. Oquendo, (unknown), Maura Boldrini, Kevin Malone, Steven P. Ellis, Gregory M. Sullivan, Thomas B. Cooper, Shan Xie, Dianne Currier	53
4	Validation of a Food Frequency Questionnaire to Assess Intake of n-3 Polyunsaturated Fatty Acids in Subjects with and without Major Depressive Disorder 2010 ·Journal of the American Dietetic Association ·M. Elizabeth Sublette, C. J. Segal-Isaacson, Thomas B. Cooper, Shiva Fekri, Nora Vanegas, Hanga Galfalvy, María A. Oquendo, J. John Mann	60
5	The effects of cannabinoids on serum cortisol and prolactin in humans 2008 ·Psychopharmacology ·Mohini Ranganathan, Gabriel Braley, Brian Pittman, Thomas B. Cooper, Edward Perry, John H. Krystal, Deepak Cyril D’Souza	89
6	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction 2005 ·Biological Psychiatry ·Deepak Cyril D’Souza, Walid Abi‐Saab, Steven Madonick, Kimberlee Forselius-Bielen, (unknown), Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, John H. Krystal	452
7	Higher cortisol levels in spring and fall in patients with major depression 2005 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Leo Sher, María A. Oquendo, Hanga Galfalvy, Gil Zalsman, Thomas B. Cooper, J. John Mann	17
8	Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder 2004 ·Psychopharmacology ·Nunzio Pomara, Lisa M. Willoughby, John J. Sidtis, Thomas B. Cooper, David J. Greenblatt	41
9	Baseline Plasma GABA: Its Relationship to the Adverse Effects of Acute Lorazepam Administration on Cognition in the Elderly 2004 ·Neurochemical Research ·Nunzio Pomara, Lisa M. Willoughby, John J. Sidtis, P. Murali Doraiswamy, Keith Wesnes, Thomas B. Cooper, David J. Greenblatt	0
10	Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics 2003 ·American Journal of Psychiatry ·Jean-Pierre Lindenmayer, Pál Czobor, Jan Volavka, Leslie Citrome, Brian Sheitman, Joseph P. McEvoy, Thomas B. Cooper, Miranda Chakos, Jeffrey A. Lieberman	353
11	Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls 2003 ·Psychoneuroendocrinology ·Leo Sher, María A. Oquendo, Shuhua Li, Steven P. Ellis, Beth S. Brodsky, Kevin Malone, Thomas B. Cooper, J. John Mann	30
12	Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association 2002 ·Journal of Clinical Psychopharmacology ·Pál Czobor, Jan Volavka, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P. McEvoy, Thomas B. Cooper, Miranda Chakos, Jeffrey A. Lieberman	147
13	Lower Cortisol Levels in Depressed Patients with Comorbid Post-Traumatic Stress Disorder 2002 ·Neuropsychopharmacology ·María A. Oquendo, (unknown), Hanga Galfalvy, Michael F. Grunebaum, Ainsley K. Burke, Álvaro Barrera, Thomas B. Cooper, Kevin Malone, J. John Mann	98
14	Relationship between ambient air pollution and DNA damage in Polish mothers and newborns. 1998 ·Environmental Health Perspectives ·Robin M. Whyatt, R M Santella, W Jedrychowski, Seymour Garte, Douglas A. Bell, Ruth Ottman, (unknown), Greg Cosma, Tie Lan Young, Thomas B. Cooper, M C Randall, D Manchester, Frederica P. Perera	83
15	The efficacy of melatonin in the treatment of jet lag 1998 ·Nordic Journal of Psychiatry ·Robert L. Spitzer, Michael Terman, Ulrik Fredrik Malt, F Singer, Jiuan Su Terman, Janet B. W. Williams, Alfred J. Lewy, Thomas B. Cooper	1
16	Behavioral and Cardiovascular Effects of Intravenous Methylphenidate in Normal Subjects and Cocaine Abusers 1997 ·European Addiction Research ·Gene‐Jack Wang, Nora D. Volkow, Robert Hitzemann, Christopher Wong, Burton Angrist, Gail Burr, (unknown), Naomi Pappas, Angela Lu, Thomas B. Cooper, Jeffrey A. Lieberman	63
17	Uncoupling of the Noradrenergic-Hypothalamic-Pituitary-Adrenal Axis in Panic Disorder Patients 1995 ·Neuropsychopharmacology ·Jeremy D. Coplan, Daniel Pine, Laszlo A. Papp, José Antônio Baddini Martínez, Thomas B. Cooper, Leonard A. Rosenblum, Jack M. Gorman	5
18	CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. 1995 ·PubMed ·Robin M. Whyatt, Seymour Garte, Greg Cosma, Douglas A. Bell, Wiesław Jędrychowski, J. Wahrendorf, M C Randall, Thomas B. Cooper, Ruth Ottman, Decai Tang	46
19	Dopaminergic sensitivity and cocaine abuse: Response to apomorphine 1990 ·Psychiatry Research ·Eric Hollander, Edward V. Nunes, Concetta DeCaria, Frederic M. Quitkin, Thomas B. Cooper, Steven Wager, Donald F. Klein	30
20	Formation of fatty acid ethyl esters during chronic ethanol treatment in mice 1988 ·Biochemical Pharmacology ·Basalingappa L. Hungund, Dora B. Goldstein, (unknown), Thomas B. Cooper	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact